Table 1.
Clinical, radiological and pathological characteristics of included donors
ABC score31N
| Control | AD | Typical AD | Atypical AD | |
|---|---|---|---|---|
| Clinical characteristics | ||||
| N (phenotype) | 10 | 19 | 10 | 9 (6 B/D, 3 PCA) |
| Gender M/F (%M) | 4/6 (40%) | 16/3 (84%)* | 9/1 (90%) | 7/2 (78%) |
| APOE genotype N | 9 | 19 | 10 | 9 |
| ε4 non-carrier | 5 (56%) | 7 (37%) | 5 (50%) | 2 (22%) |
| ε4 heterozygous | 4 (44%) | 10 (53%) | 4 (40%) | 6 (67%) |
| ε4 homozygous | – | 2 (10%) | 1 (10%) | 1 (11%) |
| Age at disease onset | 60 ± 10 | 61 ± 8 | 59 ± 13 | |
| years, mean ± SD | 1 n.a. | 1 n.a. | ||
| EAOD/LOAD (%EOAD) | 14/4 (78%) | 7/3 (70%) | 7/1 (88%) | |
| 1 n.a. | 1 n.a. | |||
| Age at death | 69 ± 7 | 67 ± 12 | 70 ± 11 | 64 ± 12 |
| years, mean ± SD | ||||
| Disease duration | – | 8 ± 5 | 10 ± 6 | 6 ± 3 |
| years, mean ± SD | ||||
| Post-mortem delay | 549 ± 114 | 478 ± 116 | 520 ± 95 | 432 ± 124 |
| min, mean ± SD | ||||
| Radiologic characteristics | ||||
| NBV (L) mean ± SD | 1.49 ± 0.06 | 1.41 ± 0.13* | 1.42 ± 0.13 | 1.40 ± 0.14 |
| NGMV (L) mean ± SD | 0.76 ± 0.04 | 0.67 ± 0.09** | 0.68 ± 0.07 | 0.67 ± 0.11* |
| NWMV (L) mean ± SD | 0.72 ± 0.03 | 0.73 ± 0.08 | 0.73 ± 0.09 | 0.73 ± 0.08 |
| Pathological characteristics | ||||
| 10 | 19 | 10 | 9 | |
| A 0/1/2/3 | 3/6/1/0 | 0/0/0/19*** | 0/0/0/10*** | 0/0/0/9*** |
| B 0/1/2/3 | 3/7/0/0 | 0/0/4/15*** | 0/0/3/7*** | 0/0/1/8*** |
| C 0/1/2/3 | 10/0/0/0 | 0/0/4/15*** | 0/0/3/7*** | 0/0/1/8*** |
| Thal phase4N | 10 | 19*** | 10*** | 9** |
| 0/1/2/3/4/5 | 3/3/3/1/0/0 | 0/0/0/1/1/17 | 0/0/0/1/0/9 | 0/0/0/0/1/8 |
| Braak NFT stage5N | 10 | 19*** | 10*** | 9** |
| 0/1/2/3/4/5/6 | 3/6/1/0/0/0/0 | 0/0/0/0/4/8/7 | 0/0/0/0/3/3/4 | 0/0/0/0/1/5/3 |
| CAA type N | 10 | 19 | 10 | 9 |
| Type 1/type 2 (% type 1) | 0/0 | 15/3 (83%) | 7/2 (78%) | 8/1 (89%) |
AD, Alzheimer’s disease; B/D, behavioral/dysexecutive variant; CAA, cerebral amyloid angiopathy; EOAD, early onset Alzheimer’s disease; L, litre; LOAD, late onset Alzheimer’s disease; M/F, males/females ratio; N, sample size; n.a., not available; NBV, normalized brain volume; NGMV, normalized grey matter volume; NWMV, normalized white matter volume; NFT, neurofibrillary tangles; PCA, posterior cortical atrophy; SD, standard deviation.
*
P < 0.05,
**
P < 0.01,
***
P < 0.001 when compared to controls.